GICS Sector : Healthcare
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally.The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients.It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials.
Guardant Health delivered a robust Q4 2025, with total revenue increasing 39% to $281.3 million, and oncology revenue rising 30% to $189.9 million. The company's non-GAAP gross margin improved to 66% in Q4, up from 63% in the prior year. For the full year, total revenue grew 33% to $982.0 million, with oncology revenue increasing 26% to $683.6 million. The actual EPS came out at '-0.5' relative to estimates at '-0.42'. Analysts estimate next year's revenue growth at 28.1%.
Publication Date: Feb -22
The company's oncology business continued to drive growth, with Guardant360 liquid volumes increasing nearly 30%, and Reveal being the fastest-growing oncology product. The Smart Platform is driving a step change in oncology volumes, with new applications and Medicare reimbursement for CRC surveillance contributing to the growth. The data business also delivered strong results, with biopharma and data revenue growing 18% to $210.1 million.
Shield, the company's blood-based screening test, has delivered extraordinary growth since its launch, with $35 million in testing revenue in Q4, driven by approximately 38,000 tests. According to AmirAli Talasaz, "Shield is the most successful diagnostic launch in history outside of COVID testing and is positioned to be a significant multiyear growth driver." The company expects Shield revenue to be in the range of $162 million to $174 million in 2026, driven by 210,000 to 225,000 tests.
With a P/S Ratio of 13.64 and an EV/EBITDA of -40.24, the market is pricing in significant growth expectations for Guardant Health. The company's guidance for 2026 revenue growth of 27% to 30% is in line with analyst estimates. As the company continues to invest in R&D and expand its commercial infrastructure, it's well-positioned to drive long-term growth. The recent acquisition of MetaSight Diagnostics and the launch of a direct-to-consumer pilot for Shield are expected to contribute to the company's growth momentum.
The company is making progress in its regulatory strategy, with a potential FDA submission for ADLT pricing in the second half of 2026. The passage of the MCED legislation is a positive development for the field, and Guardant Health is well-positioned to benefit from the growing demand for MCED tests. With a strong track record of innovation and a robust pipeline, Guardant Health is poised for continued growth and success.
Cloudflare, ServiceNow, And Guardant Health Are Among Top 10 Large-Cap Losers Last Week (April 6-April 10): Are the Others in Your Portfolio?
Apr -12
Terilyn Monroe Sells 3,832 Shares of Guardant Health (NASDAQ:GH) Stock
Apr -09
Guardant Health: Leveraging Liquid Biopsy Testing Momentum
Apr -06
Guardant Health, Inc. $GH is Capricorn Fund Managers Ltd’s 6th Largest Position
Apr -06
Guardant Health, Inc. (NASDAQ:GH) Receives Consensus Rating of “Moderate Buy” from Analysts
Apr -05
Guardant Health's InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan
Mar -30
Connective Portfolio Management LLC Acquires Shares of 7,000 Guardant Health, Inc. $GH
Mar -26
Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data
Mar -24
Guardant Health's Precision Oncology Testing growth is driven by increasing adoption of liquid biopsies, rising demand for non-invasive cancer diagnostics, and growing use of biomarkers in personalized medicine. Additionally, expanding reimbursement coverage, strategic partnerships, and investments in R&D are fueling growth, with a 14.0% growth rate.
Guardant Health's Development Services and Other segment growth of 18.0% is driven by increasing demand for its non-invasive genomic testing and analytics services, expansion into new markets, and strategic partnerships with pharmaceutical and biotechnology companies. Additionally, the company's investments in digital health and artificial intelligence are enhancing its service offerings, contributing to the segment's growth.
A comprehensive liquid biopsy test that analyzes circulating tumor DNA (ctDNA) to detect cancer mutations in the blood.
A comprehensive liquid biopsy test that analyzes ctDNA to detect cancer mutations in the blood, with a broader gene panel than Guardant360.
A non-invasive, early cancer detection test that analyzes ctDNA in the blood to detect cancer at an early stage.
A non-invasive, early cancer detection test that analyzes ctDNA in the blood to detect cancer at an early stage, with a focus on multi-cancer detection.
A liquid biopsy test that analyzes ctDNA in the blood to detect cancer mutations, with a focus on companion diagnostics and clinical trials.
Guardant Health, Inc. has a low threat of substitutes due to its unique liquid biopsy technology and strong patent portfolio, making it difficult for competitors to replicate its products.
Guardant Health, Inc. has a medium bargaining power of customers due to the presence of a few large customers, but the company's products are highly specialized and critical to patient care, limiting the customers' bargaining power.
Guardant Health, Inc. has a low bargaining power of suppliers due to its ability to negotiate prices with suppliers and its diversified supply chain, reducing dependence on any single supplier.
Guardant Health, Inc. has a high threat of new entrants due to the growing demand for liquid biopsy and the increasing interest in the field, making it attractive for new companies to enter the market.
Guardant Health, Inc. operates in a competitive market, but its strong brand recognition, patented technology, and established customer base help to mitigate the intensity of rivalry.
| Value | |
|---|---|
| Debt Weight | 88.04% |
| Debt Cost | 3.95% |
| Equity Weight | 11.96% |
| Equity Cost | 8.55% |
| WACC | 4.50% |
| Leverage | 736.00% |
Value: 8.0
Growth: 4.7
Quality: 6.4
Yield: 0.0
Momentum: 10.0
Volatility: 2.3
1-Year Total Return ->
Value: 4.4
Growth: 6.0
Quality: 3.5
Yield: 0.0
Momentum: 9.0
Volatility: 3.3
1-Year Total Return ->
Value: 1.1
Growth: 5.2
Quality: 4.6
Yield: 0.0
Momentum: 8.0
Volatility: 4.7
1-Year Total Return ->
Value: 2.9
Growth: 3.1
Quality: 5.6
Yield: 0.0
Momentum: 3.0
Volatility: 6.3
1-Year Total Return ->
Value: 2.6
Growth: 2.8
Quality: 7.2
Yield: 0.0
Momentum: 4.0
Volatility: 3.7
1-Year Total Return ->
Value: 9.0
Growth: 1.3
Quality: 3.2
Yield: 0.0
Momentum: 1.0
Volatility: 2.7
1-Year Total Return ->